Kisspeptin

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, cleaved from a 145-amino acid precursor into four bioactive fragments: kisspeptin-54 (predominant circulating form, half-life approximately 28 minutes), kisspeptin-14, kisspeptin-13, and kisspeptin-10 (half-life approximately 3 minutes). All fragments share a C-terminal RF-amide motif that binds to KISS1R (also designated GPR54), a seven-transmembrane G-protein-coupled receptor encoded on chromosome 19p13.3 in humans.

Receptor activation dissociates Gαq/11-GTP and Gβγ subunits, engaging phospholipase C-β. This generates inositol-1,4,5-triphosphate (IP3) and diacylglycerol, which mobilize intracellular calcium and activate protein kinase C and MAPK pathways (ERK1/2 and p38). In GnRH neurons — over 90% of which express KISS1R — kisspeptin causes membrane depolarization through TRPC-like cationic channels and suppresses inward-rectifier potassium channels, directly stimulating GnRH secretion into the portal circulation.

Arcuate nucleus kisspeptin neurons co-express neurokinin B and dynorphin, forming the KNDy system. Neurokinin B provides excitatory autosynaptic drive; dynorphin imposes inhibitory braking. Their interaction generates pulsatile GnRH release, governing downstream LH and FSH secretion from the anterior pituitary. A second kisspeptin neuron population in the preoptic area responds to rising estradiol and mediates the pre-ovulatory LH surge.

The strongest human evidence concerns kisspeptin-54 as an ovulation trigger in assisted reproduction. A proof-of-concept dose-escalation trial by Jayasena et al. (Journal of Clinical Investigation, 2014; n=53 subfertile women) showed a single subcutaneous injection at 1.6–12.8 nmol/kg triggered oocyte maturation at all doses, yielding a 23% clinical pregnancy rate and 10 live births. A Phase 2 multi-dose trial (JCEM, 2015; n=60 women at high OHSS risk) tested doses of 3.2–12.8 nmol/kg; oocyte maturation occurred in 95% of participants, no moderate or severe OHSS was observed, and live birth rates per embryo transfer reached 45.1% at the 9.6 nmol/kg dose. A subsequent Phase 2 RCT (Human Reproduction, 2017) demonstrated that a second kisspeptin-54 dose further improved oocyte maturation outcomes.

In hypothalamic amenorrhea, a single-blinded placebo-controlled study (n=5 women) using IV kisspeptin-54 infusion at 0.01–1.0 nmol/kg/h produced a threefold increase in LH pulse frequency and a sixfold increase in LH secretory mass per pulse versus vehicle. A 2025 randomized, double-blinded crossover trial (n=34) showed intranasal kisspeptin-54 at 12.8 nmol/kg acutely stimulated LH in healthy men (+4.4 IU/L above baseline), healthy women (+1.4 IU/L), and hypothalamic amenorrhea patients (+4.4 IU/L), with no adverse events in any group.

Genetic evidence provides foundational validation: loss-of-function mutations in KISS1R/GPR54 cause normosmic idiopathic hypogonadotropic hypogonadism, with more than 20 pathogenic variants described in the literature. Activating KISS1R mutations cause central precocious puberty.

Exploratory mechanistic studies suggest additional roles: a KP-54 infusion study reported approximately 20% increases in bone formation markers (osteocalcin), and fMRI research found enhanced limbic activation and 56% greater penile tumescence versus placebo in men with low sexual desire. These are preliminary findings from small, single-center studies and should not be generalized.

Typical dosage: 1-10 mcg (as prescribed).

All dosing information below reflects protocols reported in published clinical research and investigational trials. No kisspeptin preparation is approved by the FDA or EMA for any therapeutic indication.

• IVF oocyte maturation trigger (best-supported use): kisspeptin-54 at 9.6 nmol/kg subcutaneous single injection administered approximately 36 hours before oocyte retrieval. Phase 2 trials tested a range of 3.2–12.8 nmol/kg; 9.6 nmol/kg yielded the highest live birth rates (up to 62% per transfer) in high-OHSS-risk women.

• Hypothalamic amenorrhea — IV research setting: kisspeptin-54 at 0.01–1.0 nmol/kg/h by continuous IV infusion for 480–600 minutes. Chronic outpatient protocols using twice-weekly subcutaneous injections at 6.4 nmol/kg have been investigated without inducing tachyphylaxis over 8 weeks.

• Intranasal (investigational, not commercially available): 12.8 nmol/kg kisspeptin-54 produced acute LH stimulation in a 2025 crossover trial.

• Acute IV bolus in research volunteers: kisspeptin-10 at 0.3–1.0 nmol/kg IV, or infusion at approximately 3.07 nmol/kg/h, has been used in HPG axis physiology studies in healthy men.

Continuous high-frequency administration desensitizes KISS1R and paradoxically suppresses GnRH pulsatility; twice-weekly dosing intervals appear to preserve responsiveness. This information is educational only and does not constitute medical advice.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Within IVF protocols, kisspeptin-54 has been studied as a replacement for the conventional hCG or GnRH agonist trigger in women at elevated OHSS risk. This substitution is supported by Phase 2 randomized trial evidence and represents the only combination context with meaningful clinical data.

Within the KNDy system, kisspeptin and neurokinin B (NKB) are functionally coupled signals at the level of the arcuate nucleus. NK3R antagonists targeting the NKB pathway are separately under Phase 2/3 clinical development for menopausal vasomotor symptoms, PCOS, and endometriosis. Combining kisspeptin agonism with NK3R antagonism to modulate GnRH pulsatility is discussed in review literature (Endocrine Reviews, 2024) but has not been evaluated in formal human combination trials; evidence for this approach is preliminary.

MVT-602, a longer-acting KISS1R agonist, has shown similar LH amplitude responses to kisspeptin-54 in small investigational studies and is considered a potential substitute. Combining kisspeptin or KISS1R agonists with pulsatile GnRH for idiopathic hypogonadotropic hypogonadism is at the preclinical and expert opinion level only.

Evidence for all non-IVF combination strategies is preliminary or anecdotal. No evidence-based combination protocol has been established for any indication outside supervised IVF treatment.

Kisspeptin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally safe in clinical use

Kisspeptin has demonstrated a favorable short-term safety profile across published human trials. Across approximately 175 participants in three Phase 2 IVF trials (2014–2017), no moderate, severe, or critical ovarian hyperstimulation syndrome (OHSS) occurred, and no adverse events were directly attributed to kisspeptin-54 — a meaningful safety advantage over conventional hCG triggers. Blood pressure and heart rate remained unaffected in IV, subcutaneous, and intranasal studies. A 2025 intranasal crossover trial (n=34) and a hypothalamic amenorrhea IV infusion study (n=5) each reported no adverse events of any severity.

Tachyphylaxis is a documented pharmacological effect: continuous or high-frequency administration desensitizes KISS1R and suppresses GnRH pulsatility, analogous to GnRH agonist-induced downregulation. Twice-weekly subcutaneous dosing appears to preserve receptor responsiveness over at least 8 weeks; very frequent dosing is not appropriate for chronic reproductive therapy.

Long-term human safety has not been established. All published trials have been short in duration and enrolled small patient cohorts. Theoretical contraindications include hormone-sensitive malignancies (breast, prostate, ovarian, and endometrial cancers) given kisspeptin's stimulatory effects on gonadotropins and downstream sex steroids. Paradoxically, chronic continuous suppressive administration is under investigation for hormone-dependent cancers but remains experimental.

Kisspeptin holds no regulatory approval from any major agency. Research-grade peptide preparations sold outside supervised clinical trials lack verified purity, dose accuracy, and sterility, introducing safety risks beyond those characterized in trial data.